Genentech Gets Public Hearing on Avastin, but Remains Coy on Discussing PGx Data

A company spokesperson could not verify that the company will definitely discuss pharmacogenomics data on Avastin at the June 28-29 hearing.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.